Valspodar

• Description :

  Valspodar (PSC 833) is a selective P-glycoprotein inhibitor that has been used as an experimental cancer treatment and chemosensitizer.

• Product Name Alternative :

  PSC 833

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  P-glycoprotein

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Valspodar.html

• Concentration :

  10mM

• Purity :

  99.27

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C([C@H](C(C)C)N(C)C([C@H](CC(C)C)N(C)C([C@H](CC(C)C)N(C)C([C@@H](C)NC([C@H](C)NC([C@H](CC(C)C)N(C)C([C@H](C(C)C)NC([C@H](CC(C)C)N(C)C(CN(C)C([C@H](C(C)C)N1)=O)=O)=O)=O)=O)=O)=O)=O)=O)N(C)[C@@H](C([C@H](C)C/C=C/C)=O)C1=O

• Molecular Formula :

  C63H111N11O12

• Molecular Weight :

  1214.62

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Bajelan E, et al. Co-delivery of NSC 123127 and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance. J Pharm Pharm Sci. 2012 Sep;15 (4) :568-82.|[2]PermissionsZ., et al. Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat.2010,40 (1) :55-61.|[3]Fei Shen, et al. Dynamic Assessment of NSC 279836 Resistance and Modulation of Multidrug Resistance by Valspodar (PSC833) in Multidrug Resistance Human Cancer Cells. JPET August 2009,330 (2) : 423-429

• Shipping Conditions :

  Blue Ice

• Storage Conditions :

  -20°C, 3 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [121584-18-7]